Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 30, 2023 2:40pm

121 Views

Post# 35761769

RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

November 30, 2023 - AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere, which won accelerated approval from the FDA about a year ago.

The U.S. Federal Trade Commission, an antitrust agency, has recently adopted a more aggressive stance on biopharma M&A deals, however the ImmunoGen deal “would have no overlap from an FTC standpoint, based on our portfolio and our market presence,” Gonzalez said Thursday.

https://www.fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid